Increased mortality among elderly patients with dementia using atypical antipsychotics

CMAJ. Canadian Medical Association Journal

Volumn 173, Issue 3, 2005, Pages 252-

  Singh, Sonal ^a   Wooltorton, Eric ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGED; BEHAVIOR DISORDER; DEATH; DEMENTIA; DRUG MONITORING; FOOD AND DRUG ADMINISTRATION; GERIATRIC PATIENT; GERONTOPSYCHIATRY; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MORTALITY; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; RISK ASSESSMENT; SCHIZOPHRENIA; SHORT SURVEY; SIDE EFFECT; TREATMENT OUTCOME;

EID: 23244442841     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.050478     Document Type: Short Survey

References (4)

1. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004;329:75-8.
2. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002;167(11): 1269-70.
3. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004;170(9):1395.
4. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. A review of the evidence. JAMA 2005;293:596-608.